The U.S. Court of Appeals for the First Circuit affirmed a lower court’s dismissal of investors’ securities fraud claims against Biogen, except in regard to a statement about an Alzheimer drug’s dose-response relationship.
Plaintiffs Nadia Shash and Amjad Khan brought a securities fraud class action against Biogen Inc., and former-upper-level executives Michael Vounatsos, Alfred W. Sandrock Jr. and Samantha Budd Haeberlein, contending that Biogen violated Sections 10(B) and 20(a) of the Securities Exchange Act by concealing data that would have established their statements regarding its Alzheimer’s drug’s clinical trials were misleading.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
